Skip to content
10-Q

Quarterly Report

Pelthos Therapeutics Inc. PTHS

0001919246-26-000070

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 11, 2026 3.48M sh
Shares Diluted Q1 2026 · Mar 31, 2026 3.31M sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 612.89K sh
Capex Q1 2026 · Mar 31, 2026 $194K
Capex Q1 2026 · Mar 31, 2025 $0
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$13.13M
Operating Cash Flow restated Q1 2026 · Mar 31, 2025 −$632K
Cash And Equivalents Q1 2026 · Mar 31, 2026 $31.98M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $17.97M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $131K
Stockholders Equity Q1 2026 · Mar 31, 2026 $35.1M
Stockholders Equity Q1 2026 · Dec 31, 2025 $38.88M
Stockholders Equity restated Q1 2026 · Mar 31, 2025 −$4.2M
Stockholders Equity restated Q1 2026 · Dec 31, 2024 −$2.71M
Current Liabilities Q1 2026 · Mar 31, 2026 $25M
Current Liabilities Q1 2026 · Dec 31, 2025 $25.99M
Total Liabilities Q1 2026 · Mar 31, 2026 $110.28M
Total Liabilities Q1 2026 · Dec 31, 2025 $91.52M
Current Assets Q1 2026 · Mar 31, 2026 $69.8M
Current Assets Q1 2026 · Dec 31, 2025 $53.41M
Total Assets Q1 2026 · Mar 31, 2026 $145.38M
Total Assets Q1 2026 · Dec 31, 2025 $130.4M
Eps Diluted Q1 2026 · Mar 31, 2026 −$3.09
Eps Diluted restated Q1 2026 · Mar 31, 2025 −$3.21
Eps Basic Q1 2026 · Mar 31, 2026 −$3.09
Eps Basic restated Q1 2026 · Mar 31, 2025 −$3.21
Sga Expense Q1 2026 · Mar 31, 2026 $21.1M
Sga Expense Q1 2026 · Mar 31, 2025 $1.64M
Rd Expense Q1 2026 · Mar 31, 2026 $186K
Rd Expense restated Q1 2026 · Mar 31, 2025 $194K
Net Income Q1 2026 · Mar 31, 2026 −$10.24M
Net Income restated Q1 2026 · Mar 31, 2025 −$1.97M
Operating Income Q1 2026 · Mar 31, 2026 −$13.09M
Operating Income restated Q1 2026 · Mar 31, 2025 −$1.83M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $1.67M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $0
Revenue Q1 2026 · Mar 31, 2026 $10.91M
Revenue Q1 2026 · Mar 31, 2025 $0